What the trial was testing
The MT-12 enrolled 1,460 patients with allergic rhinitis. The study was sponsored by ALK-Abelló and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
22% relative reduction in combined symptom score on the dust mite tablet.
The Lancet Regional Health - Europe · 2025 · NCT04145219
These findings — that in combined rhinitis symptoms on the dust mite tablet vs. inactive tablet — were published in the The Lancet Regional Health - Europe and represent the headline result of the study.
Researchers tracked outcomes across 1,460 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with allergic rhinitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
House dust mite sublingual tablets (Odactra) are FDA-approved for adults but the pediatric indication is still under review in the U.S. as of early 2026. The tablet is approved in many other countries for children. Ask an allergist about access or oral allergy drops as alternatives.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open allergic rhinitis trials
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
The trial is performed to assess efficacy and safety of Beltavac with polymerized extract of house dust mites in allergic Rhinoconjunctivitis associated or not with asthma